| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.2 | 1e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.085 | 0.006 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.091 | 0.006 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.087 | 0.008 |